INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Neumora Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NMRA

Core Viewpoint - A class action lawsuit has been filed against Neumora Therapeutics, Inc. for alleged securities fraud and unlawful business practices following disappointing clinical trial results [2][4]. Group 1: Lawsuit Details - The class action lawsuit is initiated by investors who believe Neumora and its officers engaged in securities fraud [2]. - Investors have until April 7, 2025, to request appointment as Lead Plaintiff if they purchased Neumora securities during the Class Period [3]. Group 2: Company Performance and Events - Neumora conducted its initial public offering (IPO) on September 15, 2023, selling 14.71 million shares at $17.00 per share [3]. - On January 2, 2025, Neumora announced the KOASTAL-1 study results for Navacaprant, which failed to show statistically significant improvement in key endpoints, leading to a significant stock price drop of $8.63, or 81.42%, closing at $1.97 per share [4].